Clinical trialPhase 1Terminated
Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer
- Outcome
- Stopped earlyPrincipal Investigator decided to close the study early. (Other)
- Phase
- Phase 1
- Status
- Terminated
- Study type
- Interventional
- Start
- December 2009
- Expected end
- April 2013
- Enrollment
- 24 participants
- Sites
- 1
- Primary outcomes
- Evaluate the safety and feasibility perioperative neoadjuvant zoledronic acid in patients with resectable pancreas cancer.; Evaluate whether treatment with perioperative zoledronic acid prolongs overall survival or disease free survival.
- Sponsor
- Other
- Results posted
- No
- Last update
- 22 September 2014
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 3
- BackgroundAdjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-insti… DOI 10.1097/sla.0b013e318181e4e9↗
- BackgroundPreoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of th… DOI 10.1200/jco.2007.15.8642↗
- BackgroundErlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III tri… DOI 10.1200/jco.2006.07.9525↗